P reexisting renal impairment (RI) or chronic kidney disease (CKD) in patients undergoing percutaneous coronary intervention (PCI) is associated with worse in-hospital outcomes [1] [2] [3] and reduced procedural success, probably as a reflection of more complex and calcified anatomy. 4 Mortality, myocardial infarction (MI), repeat revascularization, and bleeding complication rates are all increased after PCI compared with that of patients with normal renal function. The severity of CKD predicts clinical outcome at 1 year [1] [2] [3] 5 with adverse clinical events occurring despite routine stenting and use of glycoprotein IIb/IIIa inhibitors. 6 However, the effect of RI on late outcomes, particularly in the era of drug-eluting stent (DES) use has not been reported.
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The association between renal dysfunction and cardiac disease is well established. Patients with CKD have a greater prevalence of coronary artery disease, 7, 8 and this relationship begins in the early stages of CKD. 9, 10 Once cardiovascular disease is recognized, patients with kidney disease are at high risk for subsequent events. 11 Effective treatment strategies are limited. In the pre-DES era, patients with mild RI who were randomized to revascularization by either PCI or coronary artery bypass grafting (CABG) had a doubling of mortality at 7-year follow-up and a greater risk of requiring subsequent redo CABG. 12 After PCI with bare metal stents (BMS), the need for repeat revascularization remains high, 13 although the restenosis rate, in mild to moderate CKD, is not increased at 9 months. 14 Medium and long-term outcomes are improved compared with balloon angioplasty alone. 15 Although patients with CKD have usually been excluded from DES trials, registry data suggest that the benefits associated with their use may extend to this population. 16 Retrospective analyses have demonstrated that, in the intermediate term, despite a higher overall mortality and morbidity after PCI, patients with end-stage renal disease 17 as well as those with milder degrees of CKD 18 benefit from lower rates of target vessel revascularization with DES versus BMS placement.
Therefore, we sought to investigate the long-term clinical outcomes of patients with CKD undergoing PCI at a large, high-volume, tertiary center. The objective was to determine, through the use of our prospective PCI registry database, the impact of moderate to severe CKD on the late outcomes of unselected patients in modern routine PCI practice.
Methods

The University Health Network PCI Registry
All patients undergoing PCI at the Peter Munk Cardiac Centre in Toronto, Canada, have clinical, angiographic, procedural, and outcome variables collected prospectively and entered into a data registry by dedicated specially trained nursing personnel, as described previously. 4 All patients undergoing their first PCI procedure between April 2000 and September 2007, with available baseline creatinine and weight, were included in the current study. Estimated creatinine clearance (CrCl) was calculated using the Cockroft-Gault formula: CrCl (mL/min)ϭ([140Ϫage]ϫweight [kg])/(serum creatinine [mg/dL]ϫ72) (ϫ0.85 for women). 19 A CrClϽ60 mL/min, consistent with CKD class Ն3, 20 was considered at least moderate RI. DES use is at the discretion of the operator and is generally reserved for bifurcations or 2 of the following: diabetics, small vessels, or long lesions. Clopidogrel was given as indicated by guidelines current at the time: loading was 300 to 600 mg, maintenance for 6 weeks to 12 months dependent on stent type and clinical indication.
In-Hospital Outcomes and Definitions
In-hospital mortality and morbidity rates were calculated for each cohort. Complications were defined according to the American College of Cardiology/American Heart Association cardiac catheterization standards. 21 The definition of periprocedural MI was more inclusive than that of the American College of Cardiology/American Heart Association criteria, including all patients with creatine kinase elevations Ն2 times the upper limit of normal. Indications for PCI were defined as follows: emergent PCI included primary, facilitated, or rescue PCI (failure to reperfuse or reinfarction after thrombolytic therapy in the setting of ST-elevation MI); urgent acute coronary syndrome PCI referred to any procedure for non-ST-segment elevation acute coronary syndromes or Ͼ48 hours after ST-elevation MI; salvage PCI was defined as no surgical revascularization option. Lesion type (A/B1/B2/C) was defined according to the American College of Cardiology/American Heart Association classification. Data were available on time to event for all-cause mortality, repeat PCI, or subsequent CABG, as well as hospitalization for MI, heart failure, or stroke (defined by primary hospital coding for admission). Late major adverse cardiac events (MACE) were defined as death, repeat PCI, or CABG; and cardiovascular event-free survival was defined as freedom from death or any readmission to hospital for revascularization, MI, heart failure, or stroke.
Late Outcomes
Statistical Analysis
All data analysis was performed using SAS, version 8 The evaluation of DES versus BMS in the entire data set was truncated to 4 years of follow-up. The fully adjusted risk ratios for DES and renal dysfunction (CrClϽ60 mL/min) were determined by a nonparsimonious Cox regression analysis by forcing all variables listed in Appendix A into the model, including the interaction term DESϫCrClϽ60 mL/min. In propensity-matched cohorts, patients with DES were matched with those with BMS at a ratio of 1:2 using propensity score methods. Patients were matched on the following variables: age, gender, urgent priority, primary PCI, shock, failed thrombolysis, left ventricular grade, New York Heart Association, recent MI within 30 days before PCI, diabetes, hypertension, peripheral vascular disease, left main coronary artery disease, multivessel disease (MVD), Type C lesion, glycoprotein inhibitor use, and a preprocedure thrombolysis in MI flow Ͻ3 (Appendix B). Late outcomes for DES versus BMS stratified by renal function were evaluated by Kaplan-Meier analysis.
This study was approved by the Institutional Research Ethics Boards of the University Health Network and the Institute of Clinical Evaluative Sciences. The authors had full access to the data and take responsibility for its integrity. All authors have read and agree to the manuscript as written.
Results
Between April 2000 and September 2007, the clinical, angiographic, procedural, and outcome variables of 12 662 consecutive patients who underwent their first PCI procedure at the Peter Munk Cardiac Centre were entered into a prospective database. Baseline creatinine was available for 11 969 patients who were stratified into groups with or without at least moderate CKD, defined as a CrClϽ60 mL/min (CKD classՆ3). Long-term follow-up was available for 11 953 patients (99.9%) who constituted the total study population. CKD was present in 3070 patients (25.7%).
Clinical, Procedural, and Angiographic Characteristics
Baseline patient characteristics are shown in Table 1 . Patients with CKD were older, more likely to be female, hypertensive, or diabetic. They had a greater prevalence of other comorbidities, particularly other arteriopathies such as peripheral vascular disease, carotid stenosis, and cerebrovascular disease, were more likely to have had a previous CABG and a lower ejection fraction. They were more likely to present emergently (acute coronary syndrome, rescue, facilitated, or salvage PCI) and had a significantly greater occurrence of cardiogenic shock. Procedural and angiographic characteristics are shown in Table 2 . Patients with lower CrCl more frequently had MVD and required treatment of a greater number of vessels and lesions. They underwent more left main stem, saphenous vein graft, and complex lesion interventions. Their baseline thrombolysis in MI flow grade was lower, and they required more intra-aortic balloon pump support. The complexity of their procedures was reflected in longer fluoroscopy times. The proportion of patients treated with at least 1 stent and the proportion treated with DES did not differ between groups.
In-Hospital Outcomes
The rate of adverse in-hospital outcomes stratified according to baseline CrCl is shown in Table 3 . The in-hospital MACE rate was significantly higher in patients with CKD, driven by a markedly increased mortality and MI rate. The incidence of urgent CABG or abrupt vessel closure did not differ between groups. Access site complications, predominantly bleeding, and neurological events were significantly higher in the CKD group. The overall complication rate in this cohort was increased accordingly.
Late Outcomes
The mean follow-up period was 3.6Ϯ2.2 years (range, 0 to 7.75 years). Survival estimated by Kaplan-Meier analysis was 82.7Ϯ0.6 for the group as a whole over the 7-year follow-up period. Survival rates decreased with increasing level of CKD (PϽ0.0001) (Figure 1 ). Patients with normal renal function (CrClՆ90 mL/min) or only mild CKD (CrCl, Table 6 ). When patients were propensity matched, early divergence of the survival curves was again demonstrated, but at 4 years no survival benefit was observed (Figure 2d ).
DES Use and Late Outcomes in Patients
Discussion
We have demonstrated that the adverse impact of RI on unselected patients undergoing PCI continues to influence late outcomes even in the modern era of DES, dual antiplatelet therapy, and glycoprotein IIb/IIIa inhibitors. Patients with CKD have reduced survival and reduced MACE-free survival at long-term follow-up, and CKD is shown to be an independent predictor of both mortality and MACE. DES use in this high-risk cohort is associated with improved outcomes. Our study identified preexisting CKD of at least moderate severity in just over 25% of all-comers for PCI between 2000 and 2007 at a single institution. The definition excluded those with mild CKD (CrCl, 60 to 89 mL/min) who comprise another 36% of the population in whom outcome might also be unfavorably affected. 3 Prolonged survival of patients with renal dysfunction and the aging of the general population suggest that this proportion will continue to increase. The PCI as a strategy remains suboptimal in this group despite a relatively high procedural success rate, albeit one that is lower compared with patients with normal renal function. 4 Nevertheless, it is superior to medical therapy. 22 Observational data regarding the differential outcomes of nondialysis-dependent renal dysfunction patients undergoing revascularization by CABG or PCI are conflicting, [22] [23] [24] but, in the modern era, long-term outcomes may be equivalent. 25 Because of the high burden of comorbidities in this patient population and the higher mortality post-CABG with even mild CKD, 26 however, these patients are often not considered, or declined for surgical revascularization, and as such PCI will continue to be the preferred strategy.
Although patients with RI have an increased prevalence of associated demographic, clinical, and angiographic risk factors, our study has confirmed CKD as an important independent predictor of both late mortality and morbidity. Contrast nephropathy, itself an independent predictor of mortality post-PCI, is more frequent in patients with preexisting CKD, 27 medical therapy is often suboptimal, and other pathophysiological conditions such as insulin resistance, lipoprotein abnormalities, and platelet dysfunction, which coexist in renal patients, may all contribute to the increased mortality and morbidity burden. 6 In this large prospective registry, DES use in patients with normal renal function was associated with reduced MACE rates. This reduction was largely caused by a reduction in the need for subsequent revascularization (PCI and CABG), which is in keeping with the widely published antirestenotic effect of DES compared with that of BMS. However, selection to deployment of DES was also associated with reduced late mortality, a finding that is not reflected in the major DES randomized controlled trials. 28 Recently published observational studies have found a mortality advantage of DES at 9 months 29 and 3 years. 30 It is possible that the smaller, highly selected patient cohorts in randomized controlled trials, who generally represent a lower risk group, are not truly representative of "all comers" presenting routinely for PCI, and further, that long-term outcome measures in such trials are limited.
In patients with CKD, we observed a trend, by multivariate analysis, toward a survival advantage with DES and a significant association with reduced need for subsequent revascularization. Unadjusted univariate analysis demonstrated only an early survival advantage at 1 year, and no difference was seen between BMS and DES use by 4 years. After propensity matching, no survival advantage was demonstrated. Thus, based on our single-center data set, albeit a large one, we cannot conclude that DES use is associated with a long-term survival advantage in patients with significant RI; this issue must be further addressed by broader populationbased studies as well as randomized controlled trials. However, in a high-risk population with significant comorbidity, an early survival benefit may be a modest but valuable clinical gain.
Our data suggest that the need for repeat revascularization was reduced by DES use in patients with CKD, with a trend toward reduced subsequent PCI (Pϭ0.07). Tu et al 30 showed that DES reduced TVR rates only in certain subgroups (those patients with diabetes, long lesions, or small vessels who were at increased risk of restenosis) and although it might be anticipated that patients with renal disease would be overrepresented in these subgroups, overall, the clinically driven revascularization rates in our registry were lower than the protocol-driven repeat PCI rates reported in DES randomized controlled trials. Lemos et al observed that in patients with renal dysfunction undergoing PCI, RI itself was not an independent predictor of TVR after DES versus BMS use, although they did demonstrate an antirestenotic effect of sirolimus eluting stents versus BMS in patients with (HR: 16 That CABG-free survival might also be increased by DES use in patients with CKD was perhaps unexpected, although this observation did not persist after multivariate analysis (HR: 0.35, Pϭ0.31). This may, however, reflect the higher prevalence of complex and/or MVD in patients with CKD, which can now be considered for PCI in DES era. Although our group has demonstrated previously that patients with CKD undergoing PCI have lower procedural success rates, more frequent failure rates of stent delivery, and greater post-PCI residual stenosis compared with those with normal renal function, 4 DES compared with BMS use may allow the operator to achieve more complete revascularization. The tendency to attempt more complex lesions in more vessels may contribute to lower rates of subsequent CABG. In addition, restenosis in DES compared with that in BMS is more focal. 31 Those patients with CKD in whom revascularization is incomplete, or in whom restenosis occurs, are more likely to be treated by repeat PCI rather than CABG given the high morbidity and mortality associated with CABG in this population.
Despite reporting outcomes from a large prospective registry, our study suffers from the limitations of retrospective, observational data. Specifically, we cannot account for all possible confounding factors and, because follow-up data were collected from linkage to a provincial administrative database, we cannot report on certain types of data such as causes of death or types of clinical presentation for subsequent revascularization (acute coronary syndrome, elective, etc). In addition, acute renal failure patients were not excluded from the database, although the numbers of patients requiring immediate dialysis were small (0.08%, Table 3 ).
In summary, our data represent the longest reported follow-up of patients with RI undergoing PCI in the modern era. It is also the largest CKD cohort studied. We demonstrate that the adverse effect of CKD on both mortality and morbidity early postprocedure has a lasting impact. The use of DES in this cohort may in part mitigate the poorer late outcomes, but patients remain at high risk compared with those with normal renal function. Further, prospective studies are required. As this population continues to increase as a proportion of all comers for PCI, RI will have a growing influence on the long-term clinical outcomes of our patients.
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